Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Galectin Therapeutics Inc is a biotechnology business based in the US. Galectin Therapeutics shares (GALT) are listed on the NASDAQ and all prices are listed in US Dollars. Galectin Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$3.37|
|52-week range||$1.91 - $5.70|
|50-day moving average||$3.77|
|200-day moving average||$3.47|
|Wall St. target price||$14.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.50|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-3.16%|
|1 month (2021-09-17)||-17.00%|
|3 months (2021-07-16)||26.69%|
|6 months (2021-04-16)||53.88%|
|1 year (2020-10-16)||20.79%|
|2 years (2019-10-17)||-15.75%|
|3 years (2018-10-17)||4.99|
|5 years (2016-10-17)||296.47%|
|Gross profit TTM||$0|
|Return on assets TTM||-47.29%|
|Return on equity TTM||-105.61%|
|Market capitalisation||$199.8 million|
TTM: trailing 12 months
There are currently 2.4 million Galectin Therapeutics shares held short by investors – that's known as Galectin Therapeutics's "short interest". This figure is 14.1% down from 2.7 million last month.
There are a few different ways that this level of interest in shorting Galectin Therapeutics shares can be evaluated.
Galectin Therapeutics's "short interest ratio" (SIR) is the quantity of Galectin Therapeutics shares currently shorted divided by the average quantity of Galectin Therapeutics shares traded daily (recently around 362939.29121726). Galectin Therapeutics's SIR currently stands at 6.49. In other words for every 100,000 Galectin Therapeutics shares traded daily on the market, roughly 6490 shares are currently held short.
However Galectin Therapeutics's short interest can also be evaluated against the total number of Galectin Therapeutics shares, or, against the total number of tradable Galectin Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galectin Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Galectin Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0541% of the tradable shares (for every 100,000 tradable Galectin Therapeutics shares, roughly 54 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Galectin Therapeutics.
Find out more about how you can short Galectin Therapeutics stock.
We're not expecting Galectin Therapeutics to pay a dividend over the next 12 months.
Galectin Therapeutics's shares were split on a 1:6 basis on 22 March 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Galectin Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Galectin Therapeutics shares which in turn could have impacted Galectin Therapeutics's share price.
Over the last 12 months, Galectin Therapeutics's shares have ranged in value from as little as $1.91 up to $5.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galectin Therapeutics's is 2.2651. This would suggest that Galectin Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Galectin Therapeutics Inc. , a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc. , to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.